+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Ovarian Cancer - Pipeline Insight, 2021

  • PDF Icon

    Clinical Trials

  • May 2021
  • Region: Global
  • DelveInsight
  • ID: 5322454
This “Ovarian cancer - Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Ovarian cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Ovarian cancer Understanding


Ovarian cancer: Overview


Ovarian cancer is a type of cancer that begins in a woman's ovaries - the small organs in the female reproductive system that create eggs. This kind of cancer can be difficult to detect because it often doesn't cause any symptoms until later stages. Once found, ovarian cancer can be treated with chemotherapy and surgery to remove any tumors. As with most cancers, ovarian cancer becomes more common as a person gets older. The risk of ovarian cancer increases steeply from around 45 years and is greatest in those aged between 75 and 79 years. Between 5 and 15 out of 100 ovarian cancers (5 to 15%) are caused by an inherited faulty gene. Inherited genes that increase the risk of ovarian cancer include faulty versions of BRCA1 and BRCA2. Faults in these genes also increase the risk of breast cancer.

"Ovarian cancer - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ovarian cancer pipeline landscape is provided which includes the disease overview and Ovarian cancer treatment guidelines. The assessment part of the report embraces, in depth Ovarian cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ovarian cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights


The companies and academics are working to assess challenges and seek opportunities that could influence Ovarian cancer R&D. The therapies under development are focused on novel approaches to treat/improve Ovarian cancer.

Ovarian cancer Emerging Drugs Chapters


This segment of the Ovarian cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Ovarian cancer Emerging Drugs


Atezolizumab: Genentech

Atezolizumab is a humanized kappa immunoglobulin (Ig) G1 monoclonal antibody consisting of two heavy chains (448 amino acids) and two light chains (214 amino acids) and is produced in Chinese hamster ovary cells. Atezolizumab was engineered to eliminate Fc-effector function via a single amino acid substitution (asparagine to alanine) at position 298 on the heavy chain, which results in a non-glycosylated antibody that has minimal binding to Fc receptors and, consequently, eliminates detectable Fc-effector function and depletion of cells expressing programmed death-ligand 1 (PD-L1) in humans. Atezolizumab targets human PD-L1 and inhibits its interaction with its receptors, programmed death-1 (PD-1) and B7.1, both of which can provide inhibitory signals to T cells. The drug is currently in phase 3 of clinical trials for the treatment of ovarian cancer.

Tisotumab Vedotin: Genmab

Tisotumab vedotin, also known as HuMax-TF, HuMax®-TF-ADC or TF-011-MMAE, is an antibody-drug conjugate (ADC) targeted to tissue factor (TF), a protein involved in tumor signaling and angiogenesis. Tisotumab vedotin includes an antibody targeting TF conjugated with monomethyl auristatin E (MMAE) via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. The drug is currently in phase 2 of clinical trials for the treatment of ovarian cancer.

Pembrolizumab: Merck

Keytruda (pembrolizumab) is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.

Ovarian cancer: Therapeutic Assessment


This segment of the report provides insights about the different Ovarian cancer drugs segregated based on following parameters that define the scope of the report, such as:


Major Players in Ovarian cancer


There are approx. 100+ key companies which are developing the therapies for Ovarian cancer. The companies which have their Ovarian cancer drug candidates in the most advanced stage, i.e. phase III include, Genentech.

Phases


This report covers around 100+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Ovarian cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • intravitreal
  • Subretinal
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Ovarian cancer: Pipeline Development Activities


The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ovarian cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ovarian cancer drugs.

Ovarian cancer Report Insights

  • Ovarian cancer Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Ovarian cancer Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered


Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Ovarian cancer drugs?
  • How many Ovarian cancer drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ovarian cancer?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Ovarian cancer therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Ovarian cancer and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Genentech
  • Genmab
  • AstraZeneca
  • BioNumerik Pharmaceuticals
  • On Target Laboratories
  • Gilead Sciences
  • Acerta Pharma
  • MedImmune
  • Chipscreen Biosciences
  • Aravive, Inc.
  • Allarity Therapeutics
  • AB Science
  • Syndax Pharmaceuticals
  • Merck KGaA
  • GlaxoSmithKline
  • Aprea Therapeutics
  • Verastem, Inc.
  • Clovis Oncology
  • CSPC ZhongQi Pharmaceutical
  • Immunitor LLC
  • Ellipses Pharma
  • Impact Therapeutics, Inc.
  • Eli Lilly and Company
  • BeiGene
  • Hoffmann-La Roche
  • Apexigen
  • Novartis Oncology
  • Plexxikon
  • Jiangxi Qingfeng Pharmaceutical Co. Ltd.
  • PharmaMar
  • Aprea Therapeutics
  • VBL Therapeutics
  • Tesaro, Inc.
  • Cristal Therapeutics
  • Bayer
  • Pfizer
  • Hrain Biotechnology Co., Ltd.
  • Regeneron Pharmaceuticals
  • DCPrime BV
  • PTC Therapeutics
  • AIM ImmunoTech Inc.
  • Pharmicell Co., Ltd.
  • Shattuck Labs, Inc.
  • Laekna Limited
  • Arcus Biosciences
  • Verastem, Inc.
  • Celsion

Key Products

  • Atezolizumab
  • Tisotumab Vedotin
  • Cediranib
  • Karenitecin
  • OTL38
  • Magrolimab
  • Acalabrutinib
  • Durvalumab
  • Chiauranib
  • AVB-S6-500
  • 2X-121
  • Masitinib
  • Entinostat
  • Avelumab
  • Letetresgene autoleucel
  • M6620
  • APR-246
  • VS-6766
  • Rucaparib
  • Mitoxantrone Hydrochloride
  • DP303c
  • V3-OVA
  • EP0057
  • IMP4297
  • Prexasertib
  • Pamiparib
  • Cobimetinib
  • Sevacizumab
  • Alpelisib
  • PLX2853
  • SC10914
  • Lurbinectedin
  • APR-246
  • VB-111
  • TSR-042
  • CPC634
  • BAY1895344
  • Pembrolizumab
  • Letrozole
  • anti- MESO CAR-T cells
  • REGN4018
  • DCP-001
  • PTC596
  • Rintatolimod
  • Cellgram-DC
  • SL-172154
  • Afuresertib
  • Etrumadenant
  • VS-6063
  • GEN-1

Table of Contents

IntroductionExecutive Summary
Ovarian cancer: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics
  • Comparative Analysis

Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Ovarian cancer - Analytical Perspective
In-depth Commercial Assessment
  • Ovarian cancer companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Ovarian cancer Collaboration Deals
  • Company-Company Collaborations (Licensing/Partnering) Analysis
  • Company-University Collaborations (Licensing/Partnering) Analysis

Late Stage Products (Phase III)
  • Comparative Analysis

Atezolizumab: Genentech
  • Product Description
  • Research and Development
  • Product Development Activities

Mid Stage Products (Phase II)
  • Comparative Analysis

Tisotumab Vedotin: Genmab
  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products
  • Comparative Analysis

Ovarian cancer Key CompaniesOvarian cancer Key ProductsOvarian cancer- Unmet NeedsOvarian cancer- Market Drivers and BarriersOvarian cancer- Future Perspectives and ConclusionOvarian cancer Analyst ViewsOvarian cancer Key CompaniesAppendix
List of Tables
Table 1 Total Products for Ovarian cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Ovarian cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AB Science
  • Acerta Pharma
  • AIM ImmunoTech Inc.
  • Allarity Therapeutics
  • Apexigen
  • Aprea Therapeutics
  • Aravive, Inc.
  • Arcus Biosciences
  • AstraZeneca
  • Bayer
  • BeiGene
  • BioNumerik Pharmaceuticals
  • Celsion
  • Chipscreen Biosciences
  • Clovis Oncology
  • Cristal Therapeutics
  • CSPC ZhongQi Pharmaceutical
  • DCPrime BV
  • Eli Lilly and Company
  • Ellipses Pharma
  • Genentech
  • Genmab
  • Gilead Sciences
  • GlaxoSmithKline
  • Hoffmann-La Roche
  • Hrain Biotechnology Co., Ltd.
  • Immunitor LLC
  • Impact Therapeutics, Inc.
  • Jiangxi Qingfeng Pharmaceutical Co. Ltd.
  • Laekna Limited
  • MedImmune
  • Merck KGaA
  • Novartis Oncology
  • On Target Laboratories
  • Pfizer
  • PharmaMar
  • Pharmicell Co., Ltd.
  • Plexxikon
  • PTC Therapeutics
  • Regeneron Pharmaceuticals
  • Shattuck Labs, Inc.
  • Syndax Pharmaceuticals
  • Tesaro, Inc.
  • VBL Therapeutics
  • Verastem, Inc.